On July 17, 2018 the U.S. Food and Drug Administration approved Symtuza, a four-drug combination indicated as a complete regimen for the treatment of HIV-1 infection in adults.
Adherence to HIV care visits was associated more with mental health conditions before starting antiretroviral treatment than with recent depressive symptoms, while a detectable viral load was related to such symptoms.
On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC.
Researchers found that heavy marijuana use increased the risk for complications of cardiovascular disease -- including heart attack and stroke -- regardless of whether the study participants also smoked tobacco and regardless of the presence of other...
As more people start HIV treatment, researchers are exploring ways to cut costs. Single tablets can be replaced by a few pills comprising cheaper generic drugs.
Researchers found that people taking common combinations of HIV drugs had increases in weight and body mass index, and those who were relatively thin or older prior to starting therapy were most likely to gain weight.
For the first time, scientists have shown a relationship between the proportion of key immune cells that display high levels of a gut-homing protein called alpha-4 beta-7 at the time of HIV infection and health outcomes.
Starting antiretroviral therapy immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to recent research....
Research using observational data from the HIV CAUSAL collaboration showed no significant differences in the development of resistance, allaying the concern of developing drug resistance with early antiretroviral therapy.
A revolutionary method of HIV testing of infants, dried blood spot (DBS) testing, significantly cuts the time for diagnosis.